Salta ai contenuti. | Salta alla navigazione

Strumenti personali

sito non più aggiornato
 

Sezioni

Tu sei qui: Home / Ricerca / 2009

Responsabile Roberta Rolla
Settore di ricerca Patologia Clinica
Personale docente Giorgio Bellomo   
Personale non-docente Matteo Vidali   Patrizia Pergolini                  
Obiettivi della ricerca 1) GENETIC DETERMINANTS OF RESPONSE TO WARFARIN
Risultati ottenuti 1) 70 patients on long-term therapy with a stable dose of warfarin and a target INR of 2 to 3 were retrospectively analyzed for the presence of genotype variants of CYP2C9 (*1, *2 or *3) and VKORC1 SNP 3673 (-1639G>A) by INFINITITM Warfarin assay which utilizes AutoGenomics proprietary film-based microarray technology.
41 out of 70 (59%) had a CYP2C9*1/*1 genotype while variant alleles were present respectively in 15 (21%; *1/*2), 6 (9%; *1/*3), 2 (3%; *2/*2), 5 (7%; *2/*3) and 1 (1%; *3/*3). The frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 0.17 (95%CI 0.12-0.24) and 0.09 (95%CI 0.06-0.15). With regard to the VKORC1 -1639G>A substitution, we detected 32 (46%; GG), 20 (29%) heterozygous variant (GA) and 18 (26%) homozygous variant (AA) individuals with a -1639G and -1639A allele frequency respectively of 0.60 (95%CI 0.52-0.68) and 0.40 (95%CI 0.32-0.48) in accordance with previous reports in white populations. Carriers of 2C9*2 and/or *3 allele (n=29) required a significantly lower warfarin daily dose than patients (n=41) with *1/*1 (median 1.8 mg (IQR 1.3-2.2) vs 6.1 mg (IQR 1.8-7.5); p=0.002). Difference in warfarin daily maintenance dose was also significantly different (p<0.001) between patients carrying 1 or both VKORC1 A alleles (n=38) than patients (n=32) with VKORC1 GG genotype (median 1.8 mg (IQR 1.3-2.1) vs 6.8 mg (6.1-8.3)). VKORC1 and CYP2C9 genotypes were associated with warfarin dose even after taking into account the effect of age.

 
Obiettivi della ricerca 2) The Clinical and Economic Impact of Pharmacogenomic Testing in Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
Risultati ottenuti 2) This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing for women under tamoxifen for the prevention of reoccurrence of breast cancer after breast cancer surgery. This study will use INFINITY CYP2D6 assay (AutoGenomics)
to determine a patient`s phenotype and therefore providing additional clinical information and alternative drug therapies to the patients.



 
Obiettivi della ricerca 3) VENLAFAXINE AND CYP2D6 IN CLINICAL PRACTICE.
Risultati ottenuti 3) We will recruit Caucasian patients aged 18 to 65, eligible for Venlafaxine treatment, satisfying DSM-IV criteria for major depressive episode, dysthymia or depressive adjustment disorder. Exclusion criteria will be: pregnancy, acute suicidality, alcohol/substance abuse, concomitant/prior antidepressive treatment in the previous 3 months. We will assess patients' age, gender, DSM-IV diagnosis, Venlafaxine dose, concomitant pharmacological treatment, BMI, BP, tobacco use, liver and kidney functionality. Clinical response and side effects will be monitored using CGI, HAM-D and SIDE at T0 (onset), T1 (1 week later) and T2 (6 weeks later).
The patients will be analyzed for the presence of 16 CYP2D6-genotype variants by INFINITITM CYP2D6 assay which utilizes AutoGenomics proprietary film-based microarray technology.
 
Obiettivi della ricerca 4) RUOLO DEL LABORATORIO NEL MONITORAGGIO DEL PAZIENTE IN TERAPIA ANTIAGGREGANTE.
Risultati ottenuti 4)  L'analizzatore PFA100 è largamente utilizzato nella valutazione della funzionalità piastrinica in pz in trattamento con ASA.
Tuttavia, l'applicazione tout-court di cut-off calcolati in soggetti sani a pz con differenti patologie cardiovascolari esita spesso
in falsi negativi, interpretati erroneamente come resistenza ad ASA. In questo lavoro abbiamo confrontato la metodica
PFA100 con il test di aggregazione Multiplate.
246 pz, provenienti dai reparti di Cardiologia e Chirurgia Vascolare, trattati con ASA e/o clopidogrel a differenti dosaggi,
sono stati studiati con test di funzionalità piastrinica PFA100® (sangue intero), che utilizza cartucce contenenti Collagene/
Epinefrina (Col/Epi, cut-off 165s) e Collagene/ADP (Col/ADP), e con test di aggregazione piastrinica per impedenza
Multiplate® (sangue intero) che utilizza ac. arachidonico (ASPI test, pos se <862), ADP (ADP test), o collagene (COL test,
pos se <607). 
Obiettivi della ricerca 5) BIOCHIP ARRAY TECHNOLOGY AND WORKPLACE DRUG TESTING: EVALUATING EVIDENCE RANDOX®
PERFORMANCE
Risultati ottenuti 5) Biochip Array is an emerging technology, which utilises conventional immunoassay techniques for the simultaneous measurement of analytes on a biochip surface at discrete test regions. In this preliminary study we report on performance of this technology for drug testing in the workplace setting.
60 urine specimens were evaluated by FPIA (Axsym, Abbott) and by Randox Evidence® Biochip Array Technology (Randox Laboratories Ltd., UK), which allows for simultaneous detection of 10 drug classes and creatinine.
Positive samples were confirmed by GC-MS. In order to study the effect of adulterants, human samples and blank urines spiked with different amounts of drugs were incubated with HCl, KOH, nitrites, bleach and cationic detergent. A set of
controls (Evidence DOA1 low/high, Axsym low/medium/high and Bio-Rad Liquichek C3) were run during all determinations. 
Collaborazioni in atto   
Comunicazioni a congressi   
Pubblicazioni
Impact of calibration fitting models on the clinical value of chromogranin A.
Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.
Mean platelet volume and the extent of coronary artery disease: results from a large prospective study.
Different patterns of NT-proBNP secretion in acute coronary syndromes.